Cite
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
MLA
Levin, Myron J., et al. “AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 76, no. 7, Apr. 2023, pp. 1247–56. EBSCOhost, https://doi.org/10.1093/cid/ciac899.
APA
Levin, M. J., Ustianowski, A., Thomas, S., Templeton, A., Yuan, Y., Seegobin, S., Houlihan, C. F., Menendez-Perez, I., Pollett, S., Arends, R. H., Beavon, R., Dey, K., Garbes, P., Kelly, E. J., Koh, G. C. K. W., Ivanov, S., Near, K. A., Sharbaugh, A., Streicher, K., … Esser, M. T. (2023). AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 76(7), 1247–1256. https://doi.org/10.1093/cid/ciac899
Chicago
Levin, Myron J, Andrew Ustianowski, Steven Thomas, Alison Templeton, Yuan Yuan, Seth Seegobin, Catherine F Houlihan, et al. 2023. “AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 76 (7): 1247–56. doi:10.1093/cid/ciac899.